Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
- 1 October 2002
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (19) , 4074-4082
- https://doi.org/10.1200/jco.2002.01.043
Abstract
PURPOSE: To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as a daily 1-hour infusion every...Keywords
This publication has 23 references indexed in Scilit:
- Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2002
- Cyclin-dependent Kinase 5 Promotes Insulin ExocytosisJournal of Biological Chemistry, 2001
- Bcl-2 Independence of Flavopiridol-induced ApoptosisPublished by Elsevier ,2000
- In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancerCancer Chemotherapy and Pharmacology, 1999
- Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.Journal of Clinical Investigation, 1998
- Cancer Cell CyclesScience, 1996
- Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.Proceedings of the National Academy of Sciences, 1996
- Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275Biochemical and Biophysical Research Communications, 1994
- Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased H1 kinase activityBiochemical Pharmacology, 1993
- Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275JNCI Journal of the National Cancer Institute, 1992